BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Dengue Vaccines

April 12, 2022

Despite being the first and only marketed dengue vaccine, Dengvaxia use has been limited due to major safety concerns. The dengue vaccines market is however expected to expand rapidly following the anticipated approval of TAK-003 in approximately mid-2022 to early 2023. The pipeline remains active, with two late-phase live-attenuated vaccines (LAVs), Takeda’s TAK-003 and Merck & Co’s TV003/TV005, in development in dengue-endemic regions. TV003/TV005 was initially developed by the US National Institute of Allergy and Infectious Diseases (NIAID) and has been licensed to the Butantan Institute in Brazil, where it is in Phase III trials; Merck & Co in the US, Canada, China, Europe, and Japan; and various other developers in India, the Middle East, and Asia-Pacific markets, with the goal of ensuring market access by facilitating cheaper domestic production in key dengue-endemic regions. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Dengue Fever - Vaccines and Treatments
Back to the top Back to the top